GlassScriptPhysician profile
Troy C Lund
NPI 1538357785
$64,986.83
in general payments reported to CMS, 2019-2025
8 companies · $980 in 2025
The $980 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $12K · 2021: $9,737 · 2022: $818 · 2023: $8,183 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,503 · Travel and Lodging: $1,305 · Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,503.00 |
| Travel and Lodging | $1,305.22 |
| Food and Beverage | $355.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33,444.80 | 2019 | |
| Sanofi US Services INC. | $24,784.14 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,800.00 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $817.95 | 2022 | |
| Tanabe Pharma America, INC. | $815.00 | 2025 | |
| Medexus Pharma, INC. | $164.87 | 2025 | Grafapex |
| Sobi, INC | $124.32 | 2023 | |
| Genentech USA, INC. | $35.75 | 2023 | Polivy, Columvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Lund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.